How much does a box of ruxolitinib tablets (JAKAVI) cost and market price reference

Ruxolitinib tablets (JAKAVI) is a selective Januskinase (JAK1 and JAK2< /span>) inhibitors are widely used in the treatment of myeloproliferative diseases such as polycythemia vera (PV) and myelofibrosis (MF). At present, the drug has been officially launched in China and has been included in the national medical insurance directory, bringing new hope for treatment to many patients. Although it has been included in medical insurance, the price of ruxolitinib tablets is still a focus of concern for many patients.

In the domestic market, the original drug ruxolitinib is produced by Novartis. Common specifications are 5mg, 10mg and 15mg etc. According to the latest market feedback, the price of a box of ruxolitinib tablets is approximately 3,000 yuan. The pricing of hospitals in different regions may be slightly different, and the price after medical insurance reimbursement must be based on local medical insurance policies. Generally speaking, patients who meet the conditions for medical insurance reimbursement can receive a higher proportion of cost reductions, thus greatly alleviating financial pressure.

In addition to the domestic original drug, there are also multiple versions of ruxolitinib on sale in overseas markets. For example, the price of the original research version in the Turkish market is about 4,000 yuan, which is not much different from that in China. However, due to factors such as international drug transportation, tariffs and exchange rates, the cost for patients to obtain the drug from formal overseas channels may be higher, so not all patients are suitable for overseas procurement.

For patients with greater financial burdens, generic drugs have become another practical option. At present, the price of the Bangladeshi generic version of ruxolitinib tablets is relatively affordable, with a box selling for only a few hundred yuan, and the drug ingredients are basically the same as the original drug. Although generic drugs have not yet been approved for marketing in China, some patients have reported stable efficacy after purchasing them through overseas channels, and they are one of the alternatives that can be considered. However, when purchasing generic drugs, you need to pay attention to choosing legal and safe channels to ensure drug quality and treatment safety.

Reference materials:https://www.drugs.com